Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
Article in International Immunopharmacology (April 2024)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
Article in International Immunopharmacology (April 2024)
Article in Cells (April 2024)
Article in Cell Biochemistry and Function (March 2024)